CyberKnife System Achieves 38 Percent Growth in Extracranial Treatments During Fiscal...(eatment time minimizing side effects and...)

To date more than 300 peer-reviewed publications support the use of CyberKnife radiosurgery for tumors throughout the body, including the brain, spine, lung, liver, pancreas and prostate. Additionally, many studies are currently underway to further explore the efficacy of the System for various cancers.

Since its inception, the CyberKnife System has treated more than 50,000 patients, with approximately 34 percent of those patients -- nearly 17,000 individuals worldwide -- receiving treatment during fiscal year 2008. During the past year, extracranial treatments have increased dramatically:

-- Prostate cancer -- During fiscal year 2008, the number of prostate cancer patients treated grew approximately 95 percent worldwide to more than 2,000 patients. In fact, more than half the patients ever treated for prostate cancer were treated during the last fiscal year.

-- Lung cancer -- Treatment of lung cancer grew by 44 percent worldwide year-over-year, surpassing more than 6,300 patients treated to date. Now, more than 90 percent of CyberKnife centers around the world are treating lung cancer.

-- Liver cancer -- The number of liver cancer treatments grew more than 70 percent worldwide during the last fiscal year, with the majority of treatment taking place outside the United States. In the United States alone, the CyberKnife System saw an increase of 52 percent in patients during fiscal year 2008.

-- Pancreatic cancer -- There was a 15 percent increase in pancreatic cancer treatment worldwide, exceeding more than 1000 patients treated to date. In fact, the United States alone saw an increase of 70 percent growth year over year.

"With a growing library of clinical studies underscoring the benefits of CyberKnife radiosurgery in treating various cancers, it is clear we are establishing a new paradigm for the radiosu
'/>"/>